Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of Randomised Controlled Trials

This systematic review pooled eight randomized NMN trials involving 342 adults to test whether short-term NMN supplementation improves conventional glucose-control or lipid outcomes.

Across the pooled analyses, NMN did not significantly improve fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profiles.

The review therefore provides an important counterweight to broad metabolic-benefit claims: raising NAD-related biomarkers does not automatically translate into measurable improvements in standard glucose or lipid endpoints.

• Eight RCTs involving 342 adults were included.
• Doses ranged from 250 to 2,000 mg/day for 14 days to 12 weeks.
• No significant pooled benefit was found for fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile.
• The included evidence was short term and based mainly on relatively healthy adults.

• Only eight RCTs were available.
• Trials were small and short.
• Participants and intervention doses varied across studies.
• Most participants were relatively healthy and non-diabetic.
• Meta-analysis cannot overcome limitations or biases in the underlying trials.